219 related articles for article (PubMed ID: 33263430)
1. DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.
Armstrong N; Quek RG; Ryder S; Ross J; Buksnys T; Forbes C; Fox KM; Castro E
Future Oncol; 2021 Mar; 17(7):853-864. PubMed ID: 33263430
[No Abstract] [Full Text] [Related]
2. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.
Shah S; Rachmat R; Enyioma S; Ghose A; Revythis A; Boussios S
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884434
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
Ratta R; Guida A; Scotté F; Neuzillet Y; Teillet AB; Lebret T; Beuzeboc P
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):549-560. PubMed ID: 32367009
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.
Lang SH; Swift SL; White H; Misso K; Kleijnen J; Quek RGW
Int J Oncol; 2019 Sep; 55(3):597-616. PubMed ID: 31322208
[TBL] [Abstract][Full Text] [Related]
5. Germline Testing in Prostate Cancer: When and Who to Test.
Sokolova A; Cheng H
Oncology (Williston Park); 2021 Oct; 35(10):645-653. PubMed ID: 34669358
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
7. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
8. Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.
Cimadamore A; Lopez-Beltran A; Massari F; Santoni M; Mazzucchelli R; Scarpelli M; Galosi AB; Cheng L; Montironi R
Future Oncol; 2020 Feb; 16(5):75-80. PubMed ID: 31916449
[No Abstract] [Full Text] [Related]
9. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
[TBL] [Abstract][Full Text] [Related]
10. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer.
Rapposelli IG; Zampiga V; Cangini I; Arcangeli V; Ravegnani M; Valgiusti M; Pini S; Tamberi S; Bartolini G; Passardi A; Martinelli G; Calistri D; Frassineti GL; Falcini F; Danesi R
BMC Cancer; 2021 May; 21(1):611. PubMed ID: 34034685
[TBL] [Abstract][Full Text] [Related]
12. How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients.
Sciarra A; Frisenda M; Bevilacqua G; Gentilucci A; Cattarino S; Mariotti G; Del Giudice F; Di Pierro GB; Viscuso P; Casale P; Chung BI; Autorino R; Crivellaro S; Salciccia S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614122
[TBL] [Abstract][Full Text] [Related]
13. Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.
Hofstad M; Huang EY; Woods A; Yin Y; Desai NB; Raj GV
Crit Rev Oncog; 2022; 27(1):81-96. PubMed ID: 35993980
[TBL] [Abstract][Full Text] [Related]
14. Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer.
Wang A; Everett JN; Chun J; Cen C; Simeone DM; Schnabel F
Sci Rep; 2021 Jun; 11(1):12491. PubMed ID: 34127761
[TBL] [Abstract][Full Text] [Related]
15. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
[TBL] [Abstract][Full Text] [Related]
16. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
Swift SL; Lang SH; White H; Misso K; Kleijnen J; Quek RG
Future Oncol; 2019 Oct; 15(28):3283-3303. PubMed ID: 31535940
[TBL] [Abstract][Full Text] [Related]
17. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
[No Abstract] [Full Text] [Related]
18. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
Hu Y; Guo M
Cancer Sci; 2020 Sep; 111(9):3111-3121. PubMed ID: 32639661
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients.
Zhang D; Xu X; Wei Y; Chen X; Li G; Lu Z; Zhang X; Ren X; Wang S; Qin C
Cancer Control; 2022; 29():10732748221129451. PubMed ID: 36283420
[TBL] [Abstract][Full Text] [Related]
20. BRCAness and prostate cancer: diagnostic and therapeutic considerations.
Dhawan M; Ryan CJ
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):488-498. PubMed ID: 30131605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]